TCT 943: Durable Valve Prosthesis Performance and Sustained Symptom Relief: 2-Year Outcomes Following Transseptal Transcatheter Mitral Valve Replacement in the HighLife TSMVR Feasibility Study
Presenter:
We Recommend
Disclosures
Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:
- Consultant Fee/Honoraria/Speaker's Bureau - Edwards Lifesciences; Abbott; Bayer AG; Corvia Medical